本帖最后由 老马 于 2012-1-13 21:20 编辑
- r P' k( p# O9 A3 \. y, y
+ G7 g# Q2 l* I( x爱必妥和阿瓦斯丁的比较
, v3 K% @5 X$ \/ b
( e9 \$ }* M7 f
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/8 _% L6 D* _9 B" ] s$ t6 i
6 v( \; V& [5 H, V4 R
1 c* ^, ~ D1 ]2 ehttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/, g2 p L, d9 c. t( [; G
==================================================; z+ \0 P; o+ m$ M) F
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
' V) a- o( [' H; QPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
2 \) m6 u$ ^% {8 Q7 L# ZResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.8 O2 s6 ^6 |% N9 B/ \
|